199 related articles for article (PubMed ID: 8811493)
1. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
[TBL] [Abstract][Full Text] [Related]
2. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
[TBL] [Abstract][Full Text] [Related]
3. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
4. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
[TBL] [Abstract][Full Text] [Related]
5. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.
Sier CF; Gelderman KA; Prins FA; Gorter A
Int J Cancer; 2004 May; 109(6):900-8. PubMed ID: 15027124
[TBL] [Abstract][Full Text] [Related]
6. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
7. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
Kinouchi T; Bander NH; Kotake T
J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
[TBL] [Abstract][Full Text] [Related]
8. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.
Niwa R; Shoji-Hosaka E; Sakurada M; Shinkawa T; Uchida K; Nakamura K; Matsushima K; Ueda R; Hanai N; Shitara K
Cancer Res; 2004 Mar; 64(6):2127-33. PubMed ID: 15026353
[TBL] [Abstract][Full Text] [Related]
9. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Zatovicova M; Jelenska L; Hulikova A; Ditte P; Ditte Z; Csaderova L; Svastova E; Schmalix W; Boettger V; Bevan P; Pastorek J; Pastorekova S
Int J Oncol; 2014 Dec; 45(6):2455-67. PubMed ID: 25230982
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
[TBL] [Abstract][Full Text] [Related]
12. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
13. Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy.
Seliger B; Menig M; Lichtenfels R; Atkins D; Bukur J; Halder TM; Kersten M; Harder A; Ackermann A; Beck J; Muehlenweg B; Brenner W; Melchior S; Kellner R; Lottspeich F
Proteomics; 2003 Jun; 3(6):979-90. PubMed ID: 12833523
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma.
Oosterwijk E; Debruyne FM
World J Urol; 1995; 13(3):186-90. PubMed ID: 7550393
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.
Bleumer I; Knuth A; Oosterwijk E; Hofmann R; Varga Z; Lamers C; Kruit W; Melchior S; Mala C; Ullrich S; De Mulder P; Mulders PF; Beck J
Br J Cancer; 2004 Mar; 90(5):985-90. PubMed ID: 14997194
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
[TBL] [Abstract][Full Text] [Related]
17. Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.
Kennett RH
Curr Opin Mol Ther; 2003 Feb; 5(1):70-5. PubMed ID: 12669474
[TBL] [Abstract][Full Text] [Related]
18. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Eisenthal A; Cameron RB; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
[TBL] [Abstract][Full Text] [Related]
19. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression.
Lamers CH; Gratama JW; Pouw NM; Langeveld SC; Krimpen BA; Kraan J; Stoter G; Debets R
Hum Gene Ther; 2005 Dec; 16(12):1452-62. PubMed ID: 16390276
[TBL] [Abstract][Full Text] [Related]
20. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
